MarketPulse

biotech pipeline

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

TScan Therapeutics Posts $28.7M Q1 Loss as Pipeline Advances Toward Phase 3

TScan Therapeutics reports $28.7M Q1 loss, $1.0M revenue; $128.1M cash funds operations to H2 2027 amid Phase 3 pipeline advancement.
TCRXclinical developmentPhase 3 trial
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Healthcare's Beaten-Down Gems: Why $ISRG and $VERX Deserve a $1,000 Look

Intuitive Surgical and Vertex Pharmaceuticals trade near $425-460, offering investors two shares with $1,000 despite recent sector headwinds and competitive pressures.
JNJMDTVRTXISRGlong-term investinghealthcare stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CRISPR Therapeutics' Gene-Editing Pipeline Targets $100B+ Cardiovascular Market

CRISPR Therapeutics advances promising pipeline candidates CTX310 and CTX320 targeting cardiovascular disease, though company remains unprofitable with minimal revenue.
CRSPgene therapyType 1 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline
BenzingaBenzinga··Vandana Singh

BridgeBio Surges on Rare-Disease Momentum as Analyst Sees $93 Upside

BridgeBio Pharma jumps 12.6% after William Blair initiates coverage with Outperform rating, citing accelerating product launches and robust rare-disease pipeline.
PFEBBIOBMRNALNYregulatory approvaldrug development
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CRISPR Therapeutics Advances Gene-Editing Platform With First Approved Therapy

CRISPR Therapeutics gains FDA approval for Casgevy, its first gene-editing therapy for rare blood disorders, validating the platform with multiple pipeline candidates in development.
CRSPFDA approvalclinical trials
Investing.comInvesting.com··Chris Markoch

CRISPR Therapeutics Rallies on Pipeline Momentum Despite Quarterly Losses

CRISPR stock rallied 12% on pipeline momentum despite quarterly losses and minimal revenue, buoyed by cash reserves and CTX611 candidate progress.
VRTXCRSPrevenue recognitionbiotech pipeline